Change of drug excretory pathway by CCl4-induced liver dysfunction in rat

Biochemical Pharmacology

Volumn 74, Issue 3, 2007, Pages 488-495

  Okumura, Hirotoshi ^a   Katoh, Miki ^a   Minami, Keiichi ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

CMZ; DNA microarray; Excretion; Liver dysfunction; Transporter

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE SALT EXPORT PUMP PROTEIN; CARBON TETRACHLORIDE; CARRIER PROTEIN; CEFMETAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; FECES; LIVER DYSFUNCTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ALANINE TRANSAMINASE; ANIMALS; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; BASE SEQUENCE; CARBON TETRACHLORIDE POISONING; CEFMETAZOLE; DNA PRIMERS; HEPATITIS, TOXIC; RATS; RNA, MESSENGER;

EID: 34250725014     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.025     Document Type: Article

References (32)

1. Greenfield R.A., Gerber A.U., and Craig W.A. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis 5 (1983) S127-S136
2. Park E.J., Jeon C.H., Ko G., Kim J., and Sohn D.H. Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J Pharm Pharmacol 52 (2000) 437-440
3. Yokogawa K., Watanabe M., Takeshita H., Nomura M., Mano Y., and Miyamoto K. Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride. Int J Pharm 269 (2004) 479-489
4. Minami K., Saito T., Narahara M., Tomita H., Kato H., Sugiyama H., et al. Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol Sci 87 (2005) 296-305
5. Jeong H.G. Inhibition of cytochrome P450 2E1 expression by oleanolic acid: hepatoprotective effects against carbon tetrachloride-induced hepatic injury. Toxicol Lett 105 (1999) 215-222
6. Murakawa T., Sakamoto H., Fukada S., Nakamoto S., Hirose T., Itoh N., et al. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob Agents Chemother 17 (1980) 157-164
7. Faber K.N., Muller M., and Jansen P.L. Drug transport proteins in the liver. Adv Drug Deliv Rev 55 (2003) 107-124
8. Chandra P., and Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21 (2004) 719-735
9. Shitara Y., Sato H., and Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45 (2005) 689-723
10. Trauner M., and Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83 (2003) 633-671
11. Welage L.S., Borin M.T., Wilton J.H., Hejmanowski L.G., Wels P.B., and Schentag J.J. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole. Antimicrob Agents Chemother 34 (1990) 2369-2374
12. Theron D., Barraud de Lagerie S., Tardivel S., Pelerin H., Demeuse P., Mercier C., et al. Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line GPNT. Biochem Pharmacol 66 (2003) 579-587
13. Berezowski V., Landry C., Dehouck M.P., Cecchelli R., and Fenart L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res 1018 (2004) 1-9
14. Iwanari M., Nakajima M., Kizu R., Hayakawa K., and Yokoi T. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol 76 (2002) 287-298
15. McLean A.J., and Morgan D.J. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21 (1991) 42-69
16. 4. Arch Toxicol 34 (1975) 227-236
17. Makino I., Hashimoto H., Shinozaki K., Yoshino K., and Nakagawa S. Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases. Gastroenterology 68 (1975) 545-553
18. Cochet B., Belaieff J., Allaz A.F., Rudhardt M., Balant L., and Fabre J. Decreased extrarenal clearance of cefoperazone in hepatocellular diseases. Br J Clin Pharmacol 11 (1981) 389-390
19. Boscia J.A., Korzeniowski O.M., Snepar R., Kobasa W.D., Levison M.E., and Kaye D. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis. Antimicrob Agents Chemother 23 (1983) 385-389
20. Lopez P., Garcia-Pardo L.A., Gonzalez-Gallego J., Gonzalez P., and Tunon M.J. Alterations induced by fascioliasis and cirrhosis on the biliary excretion of cefmetazole in Wistar rats. Comp Biochem Physiol C 103 (1992) 53-56
21. Hirom P.C., Millburn P., Smith R.L., and Williams R.T. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 129 (1972) 1071-1077
22. Fleck C., and Braunlich H. Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung 40 (1990) 942-946
23. Angelin B., Arvidsson A., Dahlqvist R., Hedman A., and Schenck-Gustafsson K. Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17 (1987) 262-265
24. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68 (2005) 800-807
25. Geier A., Dietrich C.G., Voigt S., Kim S.K., Gerloff T., Kullak-Ublick G.A., et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38 (2003) 345-354
26. Kier L.D., Neft R., Tang L., Suizu R., Cook T., Onsurez K., et al. Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 549 (2004) 101-113
27. 4-induced hepatic injury. Drug Metab Dispos 31 (2003) 482-490
28. Aleksunes L.M., Scheffer G.L., Jakowski A.B., Pruimboom-Brees I.M., and Manautou J.E. Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol Sci 89 (2006) 370-379
29. Aleksunes L.M., Slitt A.M., Cherrington N.J., Thibodeau M.S., Klaassen C.D., and Manautou J.E. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 83 (2005) 44-52
30. Cherrington N.J., Slitt A.L., Li N., and Klaassen C.D. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 32 (2004) 734-741
31. Uwai Y., Saito H., and Inui K. Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet 17 (2002) 125-129
32. Khamdang S., Takeda M., Babu E., Noshiro R., Onozato M.L., Tojo A., et al. Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 465 (2003) 1-7